Pfizer Hosts Annual Meeting of Shareholders
29 April 2016 - 2:00AM
Business Wire
Declares 30-Cent Second-Quarter 2016
Dividend
The board of directors of Pfizer Inc. today declared a 30-cent
second-quarter 2016 dividend on the company’s common stock, payable
June 1, 2016, to shareholders of record at the close of business on
May 13, 2016. The second-quarter 2016 cash dividend will be the
310th consecutive quarterly dividend paid by Pfizer.
“In 2015, we returned nearly $13.1 billion to shareholders
through dividends and share repurchases,” said Ian Read, chairman
and chief executive officer. “In 2016, we continue to enhance
shareholder value through our dividend increase announced in
December 2015 and our accelerated share repurchase program executed
in March 2016. In addition, we remain focused on strengthening our
innovative and established businesses, and advancing our commercial
and late-stage pipeline, while maintaining the financial
flexibility to pursue attractive business development and other
shareholder friendly capital allocation opportunities.”
Preliminary results from the Annual Meeting of Shareholders held
today indicate that the company’s 11 director nominees were
re-elected to one-year terms and that shareholders
ratified the selection of KPMG LLP as Pfizer’s independent
registered public accounting firm for the 2016 fiscal year. In
addition, shareholders voted in support of the board-sponsored
proposal to approve, on an advisory basis, the compensation of the
company’s named executive officers.
In other voting, four shareholder proposals were not approved by
the shareholders.
The final results are subject to verification by the independent
election inspectors. The final results will be reported on a Form
8-K to be filed by Pfizer with the Securities and Exchange
Commission in the next few days.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. For more information, please visit us at
www.pfizer.com. In addition, to learn more, follow us on Twitter at
@Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is
as of April 28, 2016. The Company assumes no obligation to update
forward-looking statements contained in this release as a result of
new information or future events or developments.
This release contains forward-looking information about the
Company’s actions to enhance shareholder value, including their
potential benefits, that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the uncertainties
inherent in research and development; the uncertainties inherent in
business and financial planning, including, without limitation,
risks related to Pfizer’s business and prospects, adverse
developments in Pfizer’s markets, or adverse developments in
the U.S. or global capital markets, credit markets or
economies generally that could significantly impact Pfizer’s
ability to implement, or realize the benefits of, any business
development or capital allocation opportunity; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2015 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results,” as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160428006426/en/
Pfizer Inc.Media:Joan Campion, 212-733-2798orInvestor:Ryan
Crowe, 212-733-8160
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Oct 2023 to Oct 2024